| A protein interaction landscape of breast cancer M Kim, J Park, M Bouhaddou, K Kim, A Rojc, M Modak, M Soucheray, ... Science 374 (6563), eabf3066, 2021 | 78 | 2021 |
| RASA2 ablation in T cells boosts antigen sensitivity and long-term function J Carnevale, E Shifrut, N Kale, WA Nyberg, F Blaeschke, YY Chen, Z Li, ... Nature 609 (7925), 174-182, 2022 | 72 | 2022 |
| Peroxiredoxin-1 protects estrogen receptor α from oxidative stress-induced suppression and is a protein biomarker of favorable prognosis in breast cancer PC O’Leary, M Terrile, M Bajor, P Gaj, BT Hennessy, GB Mills, ... Breast Cancer Research 16, 1-15, 2014 | 63 | 2014 |
| Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer PC O'Leary, SA Penny, RT Dolan, CM Kelly, SF Madden, E Rexhepaj, ... BMC cancer 13 (1), 1-13, 2013 | 58 | 2013 |
| Targeting peroxiredoxin 1 impairs growth of breast cancer cells and potently sensitises these cells to prooxidant agents M Bajor, AO Zych, A Graczyk-Jarzynka, A Muchowicz, M Firczuk, ... British Journal of Cancer 119 (7), 873-884, 2018 | 53 | 2018 |
| Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL AJ Eustace, NT Conlon, MSJ McDermott, BC Browne, P O’Leary, ... Bmc Cancer 18, 1-14, 2018 | 33 | 2018 |
| Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis D Ryan, M Rafferty, S Hegarty, P O’Leary, W Faller, G Gremel, ... Pigment cell & melanoma research 23 (4), 542-553, 2010 | 28 | 2010 |
| High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients K van den Hurk, B Balint, S Toomey, PC O’Leary, L Unwin, K Sheahan, ... Melanoma Research 25 (3), 189-199, 2015 | 17 | 2015 |
| Generation of a new bioluminescent model for visualisation of mammary tumour development in transgenic mice AM Zagozdzon, P O’Leary, JJ Callanan, J Crown, WM Gallagher, ... BMC cancer 12, 1-10, 2012 | 13 | 2012 |
| A whole-genome CRISPR screen identifies AHR loss as a mechanism of resistance to a PARP7 inhibitor H Chen, ME Diolaiti, PC O'Leary, A Rojc, NJ Krogan, M Kim, A Ashworth Molecular cancer therapeutics 21 (7), 1076-1089, 2022 | 8 | 2022 |
| Resistance to ATR inhibitors is mediated by loss of the nonsense-mediated decay factor UPF2 PC O'Leary, H Chen, YU Doruk, T Williamson, B Polacco, AS McNeal, ... Cancer research 82 (21), 3950-3961, 2022 | 7 | 2022 |
| A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication in vivo TY Taha, RK Suryawanshi, IP Chen, GJ Correy, M McCavitt-Malvido, ... PLoS Pathogens 19 (8), e1011614, 2023 | 5 | 2023 |
| A single inactivating amino acid change in the SARS-CoV-2 NSP3 Mac1 domain attenuates viral replication and pathogenesis in vivo TY Taha, RK Suryawanshi, IP Chen, GJ Correy, PC O’Leary, ... bioRxiv, 2023 | 2 | 2023 |
| Adenanthin, a new peroxiredoxin inhibitor, induces a switch between estrogen receptor alpha-mediated and Src/Akt-driven signaling in breast cancer cells M Bajor, AO Zych, PC O'Leary, A Czekalska, WM Gallagher, J Golab, ... CANCER RESEARCH 75, 2015 | 2 | 2015 |
| Large tandem duplications in cancer result from transcription and DNA replication collisions Y Yang, ML Badura, PC O’Leary, HM Delavan, TM Robinson, EA Egusa, ... medRxiv, 2023.05. 17.23290140, 2023 | 1 | 2023 |
| Abstract P6-06-01: Analyzing the physical and functional protein interaction landscape of breast cancer M Kim, K Kim, B Tutuncuoglu, M Soucheray, D Swaney, F Zheng, J Park, ... Cancer Research 79 (4_Supplement), P6-06-01-P6-06-01, 2019 | | 2019 |
| Targeting BRCAness in Gastric Cancer A Ashworth, P O'Leary, ... | | 2018 |
| ROLE OF THIOL-DEPENDENT PEROXIREDOXINS IN REGULATION OF AKT SIGNALING IN BREAST CANCER M Bajor, PC O'Leary, AO Zych, WM Gallagher, J Golab, R Zagozdzon Journal of International Society of Antioxidants in Nutrition & Health 1 (1), 2016 | | 2016 |
| Abstract P5-07-09: Adenanthin, a new peroxiredoxin inhibitor, induces a switch between estrogen receptor alpha-mediated and Src/Akt-driven signaling in breast cancer cells M Bajor, AO Zych, PC O'Leary, A Czekalska, WM Gallagher, J Golab, ... Cancer Research 75 (9_Supplement), P5-07-09-P5-07-09, 2015 | | 2015 |
| Multi-platform Validation and Functional Interrogation of Peroxiredoxin 1 as a Prognostic Cancer Biomarker P O'Leary University College Dublin, 2013 | | 2013 |
Professor William M. GallagherUCD Conway Institute, University College DublinVerified email at ucd.ie
